RecruitingPhase 1NCT05631886

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

A Pilot Clinical Trial of Autologous EphA-2-Targeting Chimeric Antigen Receptor Dendritic Cell Vaccine Loaded With TP53 Mutant Peptide Plus ICIs for Local Advanced/Metastatic Solid Tumors or Relapsed/Refractory Lymphomas.

Sponsor

Chinese PLA General Hospital

Enrollment

10 participants

Start Date

Jul 4, 2023

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult Lymphoma EphA2 Overexpression TP53 R273H TP53 R175H TP53 R248Q TP53 R249S

Summary

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of TP53-EphA-2-CAR-DC vaccine; detect T cell response against TP53 mutant peptide and tumor neoepitopes after the treatment with TP53-EphA-2-CAR-DC vaccine and ICIs.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new cancer treatment that combines a special immune cell vaccine (CAR-DC) with checkpoint inhibitor drugs (ICIs) in people with advanced or hard-to-treat cancers. The treatment is designed to help the immune system better recognize and fight cancer cells. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of advanced solid tumor or relapsed/refractory lymphoma - Your tumor has tested positive for certain proteins (EphA2 and TP53 mutation) - You are in reasonably good health with an expected survival of more than 3 months **You may NOT be eligible if...** - Your tumor does not have the required protein markers - You are in poor general health - You have certain other active cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.